





Exercise therapy for spondyloarthritis: a systematic review

Item type	Systematic Review
Authors	O'Dwyer, Tom; O'Shea, Finbar; Wilson, Fiona
Citation	Exercise therapy for spondyloarthritis: a systematic review 2014 Rheumatology International
DOI	10.1007/s00296-014-2965-7
Publisher	Rheumatology international
Journal	Rheumatology International
Rights	Archived with thanks to Rheumatology International
Downloaded	21-Jun-2016 12:17:32
Link to item	http://hdl.handle.net/10147/317552

REVIEW ARTICLE

Exercise therapy for spondyloarthritis: a systematic review

Tom O'Dwyer · Finbar O'Shea · Fiona Wilson

Received: 23 December 2013 / Accepted: 4 February 2014 © Springer-Verlag Berlin Heidelberg 2014

Abstract To evaluate the effects of therapeutic exercise on pain, stiffness, quality of life, physical function, disease activity, health-related fitness and cardiovascular risk factors in adults with spondyloarthritis (SpA). Electronic databases (Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE/PubMed, PEDro, AMED, CINAHL) were systematically searched from inception to October 2013 using medical subject headings and keywords. This was supplemented by searching conference abstracts and a hand search of reference lists of included studies. Randomised and quasi-randomised studies of adults with SpA in which at least one of the comparison groups received an exercise intervention were included. Outcomes of interest were pain, stiffness, quality of life, physical function and disease activity. Secondary outcomes were health-related fitness and cardiovascular risk factors. Two reviewers independently screened studies for inclusion. Methodological quality was assessed by two reviewers using the Cochrane risk of bias tool and the PEDro scale. Twenty-four studies, involving 1,498 participants, were included. Meta-analyses were not undertaken due to clinical heterogeneity, and this review focuses on qualitative synthesis. Moderate evidence supports exercise interventions in improving physical

Electronic supplementary material The online version of this article (doi:10.1007/s00296-014-2965-7) contains supplementary material, which is available to authorized users.

T. O'Dwyer (🖂) · F. Wilson

Discipline of Physiotherapy, School of Medicine, Trinity Centre for Health Sciences, Trinity College, Dublin, Ireland e-mail: odwyertk@tcd.ie

F. O'Shea Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland function, disease activity and chest expansion compared to controls; there is low-level evidence of improved pain, stiffness, spinal mobility and cardiorespiratory function. Supervised group exercise yields better outcomes than unsupervised home exercise. The addition of aerobic components to flexibility programmes improves cardiorespiratory outcomes, but not cardiovascular risk factors. The most effective exercise protocol remains unclear. Current evidence suggests that therapeutic exercises are beneficial for adults with ankylosing spondylitis; effects on other SpA subtypes are unknown.

Keywords Ankylosing spondylitis · Spondyloarthritis · Exercise · Fitness · Cardiovascular risk

Introduction

The spondyloarthropathies (SpA) are a heterogeneous group of inflammatory arthritides that include ankylosing spondylitis (AS), reactive arthritis (ReA), enteropathic spondylitis or arthritis associated with irritable bowel disease (IBD), psoriatic arthritis (PsA) and undifferentiated spondyloarthropathy (uSpA) [1]. They are characterised by sacroiliitis with inflammatory back pain, peripheral joint pain, enthesitis, dactylitis and extra-articular manifestations including uveitis, psoriasis and IBD. SpA are associated with decreased physical function and lower health-related quality of life (QoL) [2, 3]. Depending on clinical features and imaging, SpA can be classified as predominantly axial SpA or predominantly peripheral SpA [4, 5].

Current practice guidelines recommend a combination of pharmacological and non-pharmacological treatment modalities for optimal management of patients with AS and PsA [6, 7]. Exercise programmes have shown small but beneficial effects on spinal mobility and physical function in adults with AS [8]. To our knowledge, no review has systematically examined the effect of exercise in other SpA subtypes, although exercise is frequently advised as part of their management.

Epidemiological evidence suggests that AS and PsA are associated with elevated cardiovascular risk factors and increased cardiovascular morbidity and mortality [9, 10]; however, to date, studies have not explored the effects of therapeutic exercise on cardiovascular risk factors and physical fitness parameters in SpA. The aims of this review were to assess the effects of exercise on pain, stiffness, QoL, physical function, health-related fitness and cardiovascular risk factors in adults with SpA.

Materials and methods

A protocol outlining the review strategy and methods of analysis was registered with a registry of systematic reviews (available at http://www.crd.york.ac.uk/PROS-PERO/display_record.asp?ID=CRD42013004015).

Eligibility criteria

Adults diagnosed by a rheumatologist as having AS, ReA, PsA, uSpA or enteropathic spondylitis were included. Participants under 18 years of age or with juvenile-onset SpA were excluded. Quasi-randomised and randomised controlled trials (RCT) in which at least one of the groups received exercise therapy were included. Review articles, observational studies without controls, case reports, crosssectional studies and commentaries were excluded.

For the purpose of this review, exercise-based interventions comprised one or more of the following components: range of motion (stretching), strengthening or aerobic exercise. Any dosages of exercise prescription (i.e. any frequency, intensity, mode or duration) were considered. However, interventions offering general advice to exercise without prescribing specific exercises were excluded. Exercise-based interventions delivered in an inpatient setting were excluded, unless being compared to a distinct outpatient exercise group. Studies in which exercise-based interventions were administered in conjunction with other modalities (e.g. manual therapy) were excluded.

The primary outcomes of interest to this review were pain, stiffness, disease activity, physical function and QoL. Secondary outcome variables were health-related fitness measures (cardiorespiratory, muscular strength, flexibility and body composition) and cardiovascular risk factors (blood pressure, glycaemia, metabolic syndrome, body mass index and lipid profile). Information sources and study selection

Studies were retrieved by searching electronic databases (MEDLINE/PubMed, EMBASE, PEDro, AMED, CINAHL and The Cochrane Central Register of Controlled Trials) from their inception to October 2013. Search terms were adapted for use with each database. Common keywords and medical subject headings related to three components: (1) the condition (e.g. spondyloarthritis), (2) the intervention (e.g. exercise) and (3) the study design (e.g. clinical trial) (See Supplement 1). No search restrictions (date or language) were imposed. The electronic database search was supplemented by searching abstracts of the annual meetings of the World Confederation for Physical Therapy (2003–2011), the American College of Rheumatology (2006-2012), the European League Against Rheumatism (2002-2013) and the American Physical Therapy Association (2002-2013). When only abstracts were available in the published literature, authors were contacted seeking full texts of relevant studies. Finally, a hand search of the reference lists of included studies was conducted.

Two reviewers (TOD and FW) independently screened titles and abstracts to identify studies that potentially met the eligibility criteria. Full texts of these reports were retrieved and independently assessed for eligibility by the same two reviewers. Any disagreements on inclusion were resolved by discussion to achieve consensus, and failing agreement, a third reviewer (FOS) was consulted.

Data collection and analysis

A data extraction template based on Cochrane guidelines [11] was adapted and piloted on five randomly selected studies and modified accordingly. One reviewer (TOD) recorded (1) participant characteristics, (2) details of interventions and (3) relevant outcome data (group means and standard deviations). For continuous data, the differences in group means (with 95 % CI) were calculated at clinically relevant time points (i.e. post-intervention and at follow-up). For continuous data reported on different scales, standardised mean differences with 95 % CIs were used. The calculations employed a random effects model. In trials comparing two similar exercise groups and one control group, the exercise group results were pooled for comparative purposes [12, 13]. In the event that the published data from included studies were insufficient to calculate pooled effects, study authors were contacted requesting additional data. Meta-analyses were planned but ultimately deemed inappropriate due to the heterogeneity of study designs and interventions. Due to the absence of studies exploring the effects of exercise interventions on predominantly axial and predominantly peripheral SpA, this proposed subgroup analysis was not completed. Statistical analysis was conducted using Review Manager 5.2 and SPSS 21.

Risk of bias and levels of evidence

A risk of bias appraisal of included studies was performed independently by two reviewers (TOD and FW). Disagreements between the reviewers were resolved through discussion to achieve consensus. Failing agreement, a third reviewer (FOS) arbitrated. The Cochrane Collaboration's risk of bias tool rated risk of bias across six domains as low, high or unclear [11]. The Physiotherapy Evidence Database (PEDro) scale rated methodological quality from 0 (low) to 10 (high) [14]. Fair-to-good reliability has been established for the total PEDro score [15]. Each study was ascribed a level of evidence according to the criteria of the Oxford Centre for Evidence-based Medicine [16] (Table 1). These levels of evidence provide a hierarchy of the likely best evidence. Quality of evidence for key outcomes across comparisons was evaluated following the GRADE levels of evidence [17] (Table 2).

Results

Study selection

The electronic database search returned 450 records (after the removal of duplicates), and an additional nine reports

 Table 1
 Oxford Centre for Evidence-based Medicine 2011 levels of evidence

Level of evidence	Description
Level I	Systematic review of randomised trials or <i>n</i> -of-1 trials
Level II	Randomised trial or observational study with dramatic effect
Level III	Non-randomised controlled cohort/follow-up study
Level IV	Case-series, case-control or historically con- trolled studies
Level V	Mechanism-based reasoning

Table 2 GRADE levels of evidence

Quality level Definition

were identified from the search of conference abstracts. One unpublished full-text report of a conference abstract was provided [18]; attempts to obtain full texts of other published abstracts from the authors were unsuccessful. The search strategy and selection process are summarised in Fig. 1. A total of 24 studies (18 RCT) published between 1993 and 2013 were included in this review.


Study characteristics


Study characteristics and findings are summarised in Table 3. A total of 1,460 participants with AS and 38 fulfilling the Amor criteria for SpA were included. No other SpA subtypes were examined in the included studies. The mean study sample size was 62 (SD 37; range 20–155). The ratio of participants was approximately 3:1 (male:female). Subject characteristics varied in age, disease duration, disease severity and medication use.

Exercise intervention duration ranged from 3 weeks [19] to 3 years [20]. Frequency of exercise varied from twice daily [19] to once weekly [21–23], with individual session duration ranging from 30 min [18, 24–29] to 3 h [13]. Traditional therapeutic exercises targeting flexibility, posture and respiration predominated. Other exercise protocols included aerobic exercise, strength training, proprioceptive exercise, the Global Posture Re-education (GPR) method, the Pilates method, hydrotherapy and sporting activities. Seven studies compared the effect of exercise to controls, twelve compared two or more types of exercise-based interventions, and five compared therapeutic exercise to another treatment modality (inpatient rehabilitation, balneotherapy, incentive spirometry or spa-exercise therapy).

Self-report measures of physical function, QoL, disease activity, pain and stiffness were identified as primary outcomes. Flexibility was the most commonly examined health-related fitness component; fewer studies examined cardiorespiratory fitness, while no studies examined body composition or muscular strength. Cardiovascular risk factors (cholesterol and triglycerides) were assessed in one study [29]. Follow-up measures were recorded in five studies [24, 30–33].

High	We are confident that the true effect lies close to that of the estimate of the effect
Moderate	We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different
Low	Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low	We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect





Risk of bias within studies

The methodological quality of included studies was mixed (summarised in Fig. 2), with the overall risk of bias unclear. Seven studies were deemed to have a low risk of selection bias [13, 24, 25, 29-31, 34]. Six studies used methods other than randomisation to allocate participants to groups [12, 21–23, 26, 35]. There was a high risk of performance bias due to inherent difficulties in blinding participants to exercise-based treatments. Ten studies met the criteria for blinding of outcome assessment [19, 22, 24, 27-31, 33, 36], and five studies met the criteria for reporting outcome data [13, 19, 23, 29, 34]. Reporting bias across studies is generally low or unclear; only two studies preregistered their study protocols [25, 29]. The mean PEDro score of the 18 RCTs included was 5.8 (SD 1.4; range 4-8). The six non-randomised controlled trials had a mean PEDro score of 3.5 (SD 0.5; range 3–4) (Supplement 2).

Synthesis of results

This review focused on a qualitative synthesis of the studies. A meta-analysis was not undertaken due to the heterogeneity of study designs, participants, interventions and reported outcome measures. When sufficient data were reported, individual effect sizes were calculated and presented on forest plots to provide a visual overview of results. Study results are summarised in Table 3.

Comparison 1: therapeutic exercise compared to controls

Seven studies compared therapeutic exercise interventions with controls. Three of these examined home exercise programmes (HEP) [28, 35, 37], two implemented supervised group exercise (GE) [30, 36], and one study conducted Pilates training [34]. One three-armed study compared an unsupervised GPR programme to a HEP and to controls;

References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
Comparison 1: therapeutic exercise compared to controls Altan et al. [34]; level II 29; AS (mNYC) 46.5 ± 11.2	ise compared to controls 29; AS (mNYC) 46.5 ± 11.2	Pilates: 1 h, 3 days/ week × 12 weeks	BASFI, ASQoL, BASDAI, BASMI, CE	Pilates > control in BASDAI 1.0 point [0-2.0]
	24; AS (mNYC) 43.6 ± 10.1	Control: standard care and usual physical activity		
Durmus et al. [12]; level III	25 (21:4); AS (mNYC) 37.3 ± 7.3	HEP: 20 exercises daily × 12 weeks; BASFI, SF-36, BASDAI relaxation, flexibility, strength, respiratory exercise, posture, mobilisation, stretching	BASFI, SF-36, BASDAI	Unsupervised HEP > standard care for all outcomes. BASFI: 1.05 points [0.31–1.79], BASDAI: 0.99 points [0.43–1.55] and SF-36: all subscores favoured HEP ($p < 0.001$)
	18 (14:4); AS (mNYC) 42.3 ± 8	Control: standard care		
Durmus et al. [35]; level III	19 (17:2); AS (mNYC) 35.9 ± 7.3	HEP: 12 weeks, exercises dosage not specified; 20 exercises, mobi- lisation, stretching, respiratory exercise	BASFI, pain, BASDAI, CE, FVC, FEV1, PEF, VC, MVV, 6MWT	Exercise (pooled) > control for CE: 0.88 cm [0.2–1.53] and 6MWT: 83.5 m [23.48–143.52] No significant differences between the two exercise groups
	19 (14:5); AS (mNYC) 38.1 ± 11.1	Unsupervised GPR: 12 weeks, exercises dosage not specified; warm-up, mobilisation, stretching, posture, respiratory exercise		
	13 (12:1); AS (mNYC) 43.5 ± 7.3	Control: standard care		
Ince et al. [36]; level II	15 (9:6); AS (mNYC) 33.7 ± 5.2	Supervised GE: 50 min, 3 days/ week × 3 months; multimodal pro- gramme of stretching, pulmonary exercise, step-exercise	CE, CCD, MST, OWD, FFD, VC, Physical work capacity Inclinometer: gross hip, lumbar and thoracic flexion	Supervised GE > control for CE: 1.46 cm [0.29–2.63], CCD: 1.88 cm [0.68–3.08], OWD: 2.56 cm [0.22–4.9], MST: 1.35 cm [0.14– 2.56], gross thoracic flexion: 18.6° [8.55–28.65], physical work capac- ity: 0.69 W/kg [0.26–1.12] and VC: 13.24 % [2.66–23.8]
	15 (9:6); AS (mNYC) 36.1 ± 7.2	Control		
Lim et al. [28]; level II	25 (20:5); AS 28.1 ± 7.5	HEP: 30 min, daily \times 8 weeks; 16 exercises, muscle relaxation, flex-ibility, strengthening, respiration, posture	FFD, BASFI, pain Inclinometer: cervical flex/ext, shoulder flex/abd, hip abd and knee flex	Mean (SD) not reported. Unsupervised HEP > control for inclinometer measurements (p < 0.0001), FFD $(p < 0.0001)$, BASFI $(p < 0.0001)$ and pain (p < 0.0001)
	25 (19:6); AS 28.8 ± 9.3	Control: waiting list		

Table 3 continued				
References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
Masiero et al. [30]; level II	20 (15:5); AS (mNYC) Median age: 47.5	Rehabilitation group Education: Two 3-h educational- behavioural meetings + Supervised GE: 1 h, 2 days/week for 6 weeks; flexibility, stretch- ing, proprioception, respiratory exercises + HEP: 3-4 times/week for 6 weeks	Pain (cervical, lumbar), CE, BASMI, BASDAI, BASFI, MS, Spinal mobility (goniometry): cervical flex/ext/rotation/lateral inclination, lumbo-sacral flex/ext, thoraco-lumbar rotation/lateral inclination	Mean (SD) not reported Post-intervention: Rehab > control in all measures ($p < 0.05$) except cervical flex/ext ($p = 0.08$) Rehab > education for CE ($p = 0.04$) and spinal mobility ($p < 0.05$) except cervical flex/ext ($p = 0.428$) Six-month follow-up: Rehab > control in all measures ($p < 0.05$) except cervical flex/ext ($p = 0.175$) Rehab > education for BASDAI ($p = 0.055$), BASMI ($p = 0.033$), CE ($p < 0.0055$) and spinal mobility ($p < 0.056$) except cervical flex/ext ($p = 0.428$) Education group > control for BASFI ($p = 0.02$)
	20 (16:4); AS (mNYC) Median age: 44.0	Education group Education: as above		
	22 (18:4); AS (mNYC) Median age: 47.5	Control		
Sweeney et al. [37]; level II	75 (51:24); AS 46.5	HEP: mail-delivered exercise pack- age (video, booklet, exercise wall chart) for 6 months	BASFI, BASDAI	No significant between-group differ- ences
	80 (53:27); AS 45.9	Control		
Comparison 2.1: unsupervised hon	Comparison 2.1: unsupervised home exercise compared to supervised group exercise	oup exercise		
Analay et al. [31]; level II	23 (20:3); AS (Amor) 37.6 ± 11.3	Supervised GE: 50 min, 3 days/week Pain (rest), pain (activity), MS, CE, for 6 weeks; stretching, mobili- TWD, MST, FFD, IMD, VO _{2MAX} , sation, strengthening, aerobic, BASFI postural and respiratory exercises	Pain (rest), pain (activity), MS, CE, TWD, MST, FFD, IMD, VO _{2MAX} , BASFI	No significant between-group dif- ferences post-intervention or at 3-month follow-up
	22 (18:4); AS (Amor) 34.3 ± 7.9	HEP: 50 min, 3 days/week for 6 weeks; stretching, mobilisation, strengthening, aerobic, postural and respiratory exercises		

References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
Cagliyan et al. [32]; level II	23 (18:5); AS (mNYC) 35.2 ± 7.8	HEP for 12 weeks (dosage not specified); mobilisation, stretching, respiratory and postural exercises	Pain (rest), pain (activity), stiff- ness, CE, lumbar side flexion, MST, dorsal Schober, FFD, IMD, OWD, cervical rotation, BASFI, BASDAI, SF-36	Post-intervention: HEP > GE for FFD: 9 cm [1.01– 16.97] and CE (figures not reported) GE > HEP for IMD: 16.8 cm [1.29–32.31], BASFI: 0.62 points [0.03–1.21], BASFI: 0.62 points [0.03–1.21], BASDAI: 1 point [0.16–1.84], SF-36 physical func- tion: 15 points [4.99–25.01], SF-36 physical role difficulty: 25 points [4.83–45.17] and SF-36 mental health: 10.8 points [0.52–21.08] 3-month follow-up: GE > HEP for BASFI: 0.63 points [0.04–1.22] and SF-36 physical role difficulty: 22.8 points [1.57–44.03]
	23 (20:3); AS (mNYC) 36.8 ± 9.4	Supervised GE: 1 h, 2 days/week for 12 weeks; mobilisation, stretching, respiratory and postural exercises		
Hidding et al. [27]; level II	76 (63:13); AS (mNYC) 41.5 ± 10.3 years	HEP: 30 min daily for 9 months; exercise directed at hip, peripheral joints and entire spine	Thoraco-lumbar flex/ext, CE, cervical rotation, maximum work capacity by ergometry, Sickness Impact Profile, HAQ-S, AS Func- tional Index, pain, stiffness	Post-intervention differences in change score reported GE > HEP for thoraco-lumbar flex/ ext: 0.41 cm [0.1–0.7], work capac- ity: 8.9 W [0.0–17.6] and HAQ-S: 0.05 points [0.0–0.11]
	68 (49:19); AS (mNYC) 43.7 ± 10.4 years	HEP: as above + supervised GE: 1 day/week for 9 months; 1-h exercise, 1-h sports (volleyball or badminton) and 1-h hydrotherapy		
Karapolat et al. [26]; level III	22 (15:7); AS (mNYC) 47.5 ± 11.8 years 16 (11:5); AS (mNYC)	Supervised GE: 45 min, 3 days/week BASMI, BASFI, BASDAI, NHP for 6 weeks; 10-min walk, respira- tory, stretching, mobilisation and strengthening exercises HEP: 45 min, 3 days/week for	BASMI, BASFI, BASDAI, NHP	Supervised GE > HEP for NHP sleep subscore: 17.85 points [1.19–34.51]
Ramos-Solchaga et al. [20]; level II	46.6 ± 14.8 years 24 (18:6); AS (mNYC) 207 + 107 2000	6 weeks; same as GE programme Supervised GE: 30 min, 3 days/week CCD, CE, FFD, MST	CCD, CE, FFD, MST	No significant between-group differ-
	35.6 ± 10.5 years 36.6 ± 10.5 years	Not 5 years Supervised individual exercise: 20 × 30 min sessions within 1 month (annually) + unsupervised HEP rest of the 3 years		ences reported

Table 3 continued

Betteneos: ordanec lord Contact female; condition Intervention Contact female; condition Concone meaners Significant hereon Age (mean ±2) 41 (27):43, KinNYC) H2 Pfor 3 years Age (mean ±2) (00) [9:5, CL) (00) [9:5, CL) Grappingen 12:2: global protant recolation 10 (9:1); AS (mNYC) H2 Pfor 3 years No significant here Alean 23:1: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7: 7:	Table 3 continued				
41 (27:14); AS (mNYC) HEP for 3 years 34.4 (27:14); AS (mNYC) GPR protocol: 1 days/week for 34.4 (27:14); AS (mNYC) GPR protocol: 1 days/week for 10 (9:1); AS (mNYC) GPR protocol: 1 days/week for Mom age: 51 ± 7 years 12 weeks; 0 (9:1); AS (mNYC) Supervised GE: 1 days/week for Mom age: 51 ± 6 years Supervised GE: 1 days/week for Mom age: 51 ± 6 years Supervised GE: 1 days/week for Mom age: 51 ± 6 years Supervised GE: 1 days/week for Mom age: 51 ± 6 years Supervised GE: 1 days/week for Mom age: 51 ± 6 years Supervised GE: 1 days/week for 20 (16:5); AS (mNYC) Supervised GE: 1 hweekly for 21 (15:5); AS (mNYC) Supervised GE: 1 hweekly for 21 (15:5); AS (mNYC) Supervised GE: 1 hweekly for 21 (15:5); AS (mNYC) Supervised GE: 1 hweekly for 21 (15:5); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC) Supervised GE: 1 days/week for 21 (11:1); AS (mNYC)	References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
SolutionFVC, FEV1, FEV1/FVC, CENnothin ape: 51 \pm 7 yearsGPR protocol: 1 days/week for Mean age: 51 \pm 7 yearsGPR protocol: 1 days/week for Needs main and manual structures.PVC, FEV1, FEV1/FVC, CEN10 (9:1); AS (mNYC)Supervised GE: 1 lays/week for it weeks monthy thereafter for 		41 (27:14); AS (mNYC) 34.4 ± 9.2 years	HEP for 3 years		
Image: 14 \pm NG(mNYC)CPR protocol: 1 days/week for Mean age: 54 \pm 9 yearsCPR protocol: 1 days/week for Mean age: 54 \pm 9 yearsN10 9:1). AS (mNYC)Neeks: Mean age: 54 \pm 9 yearsSupervised E:: 1 days/week for 	Comparison 2.2: global postural re-4	education			
10 (9:1): AS (mNYC)Supervised GE: 1 days/week for area age: 34 ± 6 yearsSupervised GE: 1 days/week for 12 weeks: monthy thereafter for 5 weeks: monthy thereafter for 12 monthsTWD. MST, cervical rotation, N20 (16:4): AS (mNYC)Supervised GE: 1 h weekly for 12 monthsNN20 (15:5): AS (mNYC)Supervised GE: 1 h weekly for 12 monthsNN20 (15:5): AS (mNYC)Supervised GE: 1 h weekly for 12 monthsNN20 (15:5): AS (mNYC)Supervised GE: 1 h weekly for 12 months supplemented per 13 months supplemented per 14 stretching 17 (134); AS (mNYC)NN20 (146); AS (mNYC)Supervised GE: 1 day/week for 13 months supervised GE: 1 day/week for 16 weeks; monthy thereafter for 16 weeks; monthy thereafter for 16 weeks; month per 17 (134); AS (mNYC)Supervised GE: 1 day/week for 16 weeks; month per 17 (134); AS (mNYC)N20 (146); AS (mNYC)Group gereries 17 (134); AS (mNYC)Supervised GE: 1 day/week for 16 weeks; warm-up. mobilisation 35.3 ± 12.2N20 (146); AS (mNYC)Supervised GE: 40 min. 2 day/week 60 for lo weeks 35.3 ± 12.2PN15 (12.3); AS (mNYC)Supervised GE: 40 min. 2 day/week 60 for lo weeks 35.3 ± 10.5Supervised GE: 40 min. 2 day/week 60 for weeks 35.3 ± 10.5N	Alonso-Blanco et al. [22]; level III	10 (9:1); AS (mNYC) Mean age: 51 ± 7 years	GPR protocol: 1 days/week for 12 weeks	FVC, FEV1, FEV1/FVC, CE	No significant between-group differ- ences reported
20 (16.4), AS (mNYC)Supervised GE: 1 h weekly for 1 minbar side flexion, IMD, BASFI, 1 swesk, monthly thereafter for 1 swesk, monthly thereafter for stretching, breathingTWD, MST, cervical rotation, lassDAIN 46 ± 8 15 swesk ; monthly thereafter for 15 wesk ; monthly thereafter for 		10 (9:1); AS (mNYC) Mean age: 54 ± 6 years	Supervised GE: 1 days/week for 12 weeks; spinal mobilisation, stretching, breathing		
 20 (15:5), AS (mNYC) 20 (15:5), AS (mNYC) 45 ± 9 20 (15:5), AS (mNYC) 5 weeks; monthly thereafter for 15 weeks; monthly thereafter for 17 months supplemented by HEP; warm-up, mobilisation, stretch- ing, postural exercise, respiratory exercise 12 (11:1); AS (mNYC) 20 (11:1); AS (mNYC) 30 supervised GE: 1 day/week for 16 weeks; warm-up, mobilisat- stretching 17 (13:4); AS (mNYC) 16 weeks; warm-up, mobilisa- tion, stretching, postural exercise, respiratory exercise 20 (14:6); AS (mNYC) 10 week for 16 weeks 11 (12:3); AS (mNYC) 15 (12:3); AS (mNYC) Supervised GE: 40 min, 2 day/week for 16 weeks; segmental stretch- ing, respiratory exercises 	Fernandez-de-las-Penas et al. [33]; level II	20 (16:4); AS (mNYC) 46 ± 8	Supervised GE: 1 h weekly for 15 weeks; monthly thereafter for 12 months + HEP; 20 exercises: mobilisation, stretching, breathing	TWD, MST, cervical rotation, lumbar side flexion, IMD, BASFI, BASDAI	No significant between-group differ- ences reported after intervention or at 12-month follow-up
12 (11:1); AS (mNYC)Supervised GE: 1 day/week for 16 weeks; mobilisation and stretchingSF-36N 49.8 ± 4.6 16 weeks; mobilisation and stretching57-36N 40.4 ± 7.4 17 (13:4); AS (mNYC)Group GPR: 1 day/week for 16 weeks; warm-up, mobilisa- tion, stretching, postural exercise, respiratory exercisePain (cervical, dorsal, humbar), MS, CCD, OWD, cervical, dorsal, humbar), MS, SF-36 $20 (14:6); AS (mNYC)Individual supervised GPR: 1 h/35.3 \pm 12.2Pain (cervical, dorsal, humbar), MS,SF-36In15 (12:3); AS (mNYC)Supervised GE: 40 min, 2 days/weekfor 16 weeks; segmental stretch-ing, respiratory exercisesSr-36$		20 (15:5); AS (mNYC) 45 ± 9	Group GPR: 1 h weekly for 15 weeks: monthly thereafter for 12 months supplemented by HEP; warm-up, mobilisation, stretch- ing, postural exercise, respiratory exercise		
17 (13.4): AS (mNYC)Group GPR: 1 day/week for 16 weeks; warm-up, mobilisa- tion, stretching, postural exercise, respiratory exerciseGroup GPR: 1 day/week for 16 weeks; warm-up, mobilisa- tion, stretching, postural exercise, respiratory exercise20 (14:6): AS (mNYC)Individual supervised GPR: 1 h/ week for 16 weeksPain (cervical, dorsal, lumbar), MS, In CCD, OWD, cervical rotation, FFD, MST, CE, BASDAI, HAQ-S, SF-3615 (12:3): AS (mNYC)Supervised GE: 40 min, 2 days/week for 16 weeks; segmental stretch- ing, respiratory exercises	Rivera-Navarro et al. [21]; level III	12 (11:1); AS (mNYC) 49.8 ± 4.6	Supervised GE: 1 days/week for 16 weeks; mobilisation and stretching	SF-36	No significant between-group differ- ences reported
20 (14:6); AS (mNYC)Individual supervised GPR: 1 h/ 35.3 ± 12.2Pain (cervical, dorsal, lumbar), MS, In CCD, OWD, cervical rotation, FFD, MST, CE, BASDAI, HAQ-S, SF-3615 (12:3); AS (mNYC)Supervised GE: 40 min, 2 days/week for 16 weeks; segmental stretch- ing, respiratory exercises		17 (13:4); AS (mNYC) 46.4 ± 7.4	Group GPR: 1 day/week for 16 weeks; warm-up, mobilisa- tion, stretching, postural exercise, respiratory exercise		
S (mNYC)	Silva et al. [23]; level III	20 (14:6); AS (mNYC) 35.3 ± 12.2	Individual supervised GPR: 1 h/ week for 16 weeks	Pain (cervical, dorsal, lumbar), MS, CCD, OWD, cervical rotation, FFD, MST, CE, BASDAI, HAQ-S, SF-36	Individual GPR > supervised GE for dorsal pain: 1 point [0.8–1.2], lumbar pain: 0.9 points [0.51–1.29], MS: 19.9 min [18.2–21.58], CCD: 1.7 cm [1.3–1.7], OWD: 3 cm [2.53–3.47], cervical rotation: 11.1° [10.44–11.76], MST: 0.3 cm [0.05–0.55], CE: 1.4 cm [1.19–1.61] and SF-36 physical aspects: 9.4 points [7.68–11.12]
		15 (12:3); AS (mNYC) 44.3 ± 10.6	Supervised GE: 40 min, 2 days/week for 16 weeks; segmental stretch- ing, respiratory exercises		

Table 3 continued				
References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
Comparison 2.3: aerobic exercise Karapolat et al. [38]; level II	13 (10:3); AS (mNYC) 50.2 ± 12.4 12 (8:4); AS (mNYC) 46.9 ± 13.4	Swimming: free-style, 30 min, 3 days/week for 6 weeks; 60–70 % HRR-12 bpm + HEP: 30 min, 6 days/week for 6 weeks; flexibility, stretching, respiratory exercise Walking: 30 min, 3 days/week for 6 weeks; 60–70 % pVO2, 13–15 on the Borg scale and 60–70 % HRR	BASMI, CE, FFD, BAS- DAI, BASFI, NHP, 6MWT, pVO2, RER, AT, FEV1, FVC, FEV1/FVC, VC	Swimming + HEP > HEP for 6MWT: 60.17 m [28.79–91.55]
	12 (9:3); AS (mNYC) 48.4 ± 9.5	+ riper as above HEP: as above		
Niedermann et al. [29]; level II	53 (34:19); AS (mNYC) 50.1 ± 11.9	Cardiovascular training: supervised Nordic walking, 30 min, 2 days/ week for 6 weeks; intensity 55-85 % HR _{max} + unsupervised aerobic exercise (Nordic walking or other endur- ance activity), minimum 1 days/ week for 12 weeks; intensity 55–85 % HR _{max} + Supervised GE: 1 h, 1 days/week for 12 weeks; focus on spinal flexibility	Physical work capacity, BASDAI, BASFI, BASMI, EURO-Quol, ESR, CRP, cholesterol and triglyc- erides	Cardiovascular training group > atten- tion control group for PWC: 20.2 W [18.71–21.69]
53 (34:19); , 47.6 ± 12.4 Comparison 2.4: multimodal exercise programmes	53 (34:19); AS (mNYC) 47.6 ± 12.4 See programmes	Attention control: 2.5 h, 1 day/ month for 12 weeks; discussion on coping strategies and stress reduction + Supervised GE: as above		
Rosu et al. [39]; level II	48 (39:11); AS (mNYC) 25.3 ± 3.7	HEP: 50 min, 3 days/week for 48 weeks; mixed Pilates, Heck- scher and McKenzie methods' exercises for breathing, posture	Pain, BASDAI, BASFI, BASMI, MST, FFD, CE, VC	Mixed Pilates, Heckscher and McKenzie methods HEP > mul- timodal HEP for pain: 7.5 mm [4.16-10.84], BASDAI: 2.0 points [1.5-2.6], BASFI: 1.3 points [0.7- 1.8], BASMI: 1.8 points [1.6-2.1], MST: 1.1 cm [0.8-1.3], FFD: 7.8 cm [5.4-10.2], CE: 1.49 cm [1.2-1.8] and VC: 4.3 %predicted [1.1-7.6]


References; evidence level n (n Age 48 (. 48 (. 25.0 Comparison 3.1: inpatient rehabilitation Figen et al. [19]; level II				
nt rehabilitati	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
nt rehabilitati	48 (40:8); AS (mNYC) 25.0 ± 3.8	HEP: 50 min, 3 days/week for 48 weeks: multimodal programme of stretching, pulmonary exercise, step-exercise		
42.5	n = 29 (24:5); AS (mNYC) 42.5 ± 10.6	Inpatient rehab: 15 sessions, over 3 weeks; physical therapy modali- ties, occupational therapy, thera- peutic exercise. Education and exercise and activity advice	BASDAI, BASFI	No significant between-group differ- ences
n = 37 ±	<i>n</i> = 31 (20:11); AS (mNYC) 37 ± 9.6	HEP: twice daily for 3 weeks; postural, respiratory and stretch- ing exercises, walking endurance, mobilisation. Education and exercise and activity advice		
Will et al. [18]; unpublished; level II 21 (42.4	21 (14:7): SpA (Amor) 42.4 ± 12.2	Intensive exercise: live-in 5 days/ week for 3 weeks (90-h exercise); group and individual stretching, gym exercises, hydrotherapy, aerobic fitness + HEP: 30 min daily for 12 months; stretching	BASDAI, BASFI, BASMI, CRP	No significant between-group differ- ences
17 (42.9 Communicon 3.2, Ralmoothoremy	17 (10:7); SpA (Amor) 42.9 ± 13.3	Light-intensity exercise: 2 h, 2 days/ week for 3 weeks; 1-h gym exer- cise and 1-h hydrotherapy + HEP: 30-min daily stretching for 12 months		
	n = 28, age and gender not reported	Balneotherapy: 30 min daily for 3 weeks + HEP: 30 min daily for 6 months	Pain (daily), pain (night), MS, BAS- DAI, BASFI, DFI, NHP, OWD, CCD, CE, MST, FFibD	Post-intervention: Balneotherapy + HEP > HEP for BASDAI: 0.67 points [0.2–1.14] and NHP total: 53.01 points [4.84–101.2] No significant between-group differ- ences at 6-month follow-up
n = Comparison 3.3: incentive spirometry	n = 26 age and gender not reported	HEP: 30 min daily for 6 months		
	23 (22:1); AS (mNYC) 38.0 ± 9.1	HEP: 30 min daily for 16 weeks; (20 exercises) mobilisation, stretching, breathing exercise	BASFI, BASDAI, CE, FFD 6MWT PFT: FVC, FEV1, FEV1/FVC, TLC, VC, RV	No significant between-group differ- ences

References; evidence level	n (male: female); condition Age (mean \pm SD)	Intervention	Outcome measures	Significant between-group differences (MD [95 % CI])
	23 (22:1); AS (mNYC) 34.6 ± 5.9	HEP: as above + incentive spirometry for 30 min daily for 16 weeks		
Comparison 3.4: Spa-exercise Van Tubergen et al. [13]: level II	40 (25:15); AS (mNYC)	Spa-exercise (Austria): 5 davs/week	BASFI, pain, pain (night), ASOoL.	Spa-exercise +GE (pooled
	48 土 10	for 3 weeks, for 3 weeks, morning—1-h GE, 30-min walking, 14–30-min postural correction afternoon—alternating: 1-h visit to	MS, BASDAI, HAQ-S	Tesults) > GE At 4 weeks: pain 1.1 points [0.12– 2.01] and HAQ-S 0.42 points [0.03–0.8]
		Gasteiner Heilstollen, or 30-min hydrotherapy, 30-min thermal bath- ing and 1-h sports		At 16 weeks: pain 1.1 points [0.15-2.05] At 28 or 40 weeks no significant
		+ Supervised GE (when spa-exercise therapy concluded) 3 h, 1 days/week for 37 weeks; 1-h GE, 1-h sports, 1-h hydrotherapy		between-group differences
	40 (28:12); AS (mNYC) 49 ± 9	Spa-exercise (the Netherlands): 5 days/week for 3 weeks; morning—1-h GE, 30-min walking,		
		14–30-mun postural correction afternoon—alternating: 2×15 min sauna + 30-min thermal bathing, or 30-min hydrotherapy, 30-min		
		thermal bathing and 1-h sports + Supervised GE (when spa-exercise therapy concluded) 3 h, 1 day/week		
		for 37 weeks; 1-h GE, 1-h sports, 1-h hydrotherapy		
	40 (34:6); AS (mNYC) 48 ± 10	Supervised GE: 1 day/week for 40 weeks; 1-h GE, 1-h sports, 1-h		
		hydrotherapy		
<i>abd</i> abduction, <i>AS</i> ankylosing spond Ankylosing Spondylitis Functional protein, <i>DFI</i> Dougados Functional 1	dylitis, <i>ASQoL</i> Ankylosing Spondyli Index, <i>BASMI</i> Bath Ankylosing Sp Index, <i>ESR</i> erythrocyte sedimentatic	abd abduction, AS ankylosing spondylitis, ASQoL Ankylosing Spondylitis Quality of Life, AT anaerobic threshold, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CCD chin-to-chest distance, CE chest expansion, CI confidence interval, CRP C-reactive protein, DFI Dougados Functional Index, ESR erythrocyte sedimentation rate, <i>ext</i> extension, <i>FEVI</i> forced expiratory volume in 1 s, <i>FFD</i> finger-to-floor distance, <i>FFibD</i> fingertip-fibula head	1, <i>BASDAI</i> Bath Ankylosing Spondyl chest distance, <i>CE</i> chest expansion, ory volume in 1 s, <i>FFD</i> finger-to-flo	itis Disease Activity Index, <i>BASFI</i> Bath <i>CI</i> confidence interval, <i>CRP</i> C-reactive or distance, <i>FFibD</i> fingertip-fibula head

Table 3 continued

distance, flex flexion, FVC forced vital capacity, GE group exercise, GPR global postural re-education, HAQ-S Health Assessment Questionnaire for Spondyloarthropathies, HEP home exercise programme, IMD intermalleolar distance, mNYC modified New York criteria, MS morning stiffness, MST modified Schober's test, MVV maximal voluntary ventilation, NHP Nottingham Health Profile, OWD occiput-to-wall distance, PEF peak expiratory flow, pVO2 maximal oxygen consumption, RER respiratory exchange ratio, RV residual volume, SD standard deviation, SF-36

36-item short-form survey, TLC total lung capacity, TWD tragus-to-wall distance, VC vital capacity, 6MWT 6-min walk test



results from both exercise groups were pooled for comparison with controls [12].

Function, QoL, disease activity, pain and stiffness


Physical function was measured using the Bath Ankylosing Spondylitis Functional Index (BASFI) in six of the seven studies. Four of these are presented in Fig. 3; only the study by Durmus et al. [35] significantly favoured exercise. The other two studies did not report mean and standard deviations and are not included in the figure; their findings favoured exercise over controls [28, 30]. Benefits were maintained at 6-month follow-up [30].


The results of four studies measuring disease activity on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) are presented in Fig. 3; the study by Durmus et al. [35] significantly favoured the exercise group. Masiero et al. [30] also found BASDAI scores to be significantly improved immediately after GE, and at 6-month follow-up, compared to controls. Compared to controls, spinal mobility scores on the Bath Ankylosing Spondylitis Metrology Index (BASMI) were significantly lower following a rehabilitation programme [30], but not significantly different after a Pilates intervention [34].


In comparison with controls, QoL was significantly improved following a HEP [35], but not following a Pilates-based intervention [34]. Pain and stiffness scores were significantly lower following exercise interventions and at 6-month follow-up [28, 30].

Health-related fitness outcomes


Following a 3-month multimodal GE intervention, a significant improvement was observed in physical work capacity on a bicycle ergometer and predicted vital capacity [36]. Durmus et al. [12] reported a significant increase in distance walked in a 6-min walk test (6MWT) following exercise compared to controls; no significant between-group











C HEP compared to GE in physical function

Fig. 3 Forest plot of between-group comparisons. Std standardised

differences were observed in pulmonary function tests (PFTs).

The majority of individual mobility tests were significantly improved after exercise compared to controls [28, 36]. Inclinometer and pocket goniometry assessment found significant improvements favouring exercise groups in cervical, shoulder and knee range of motion (ROM), but results for thoraco-lumbar mobility were conflicting [28, 30, 36]. Chest expansion (CE) was significantly greater in a HEP group [12], a group undergoing a multimodal intervention [36], a rehabilitation group [30], but not in a Pilates group [34], compared to controls.

Therapeutic exercise is effective for improving physical function, disease activity and CE compared to controls, and the level of evidence is moderate coming from six, five and four studies, respectively. Exercise programmes are effective at improving joint mobility, cardiorespiratory function, pain and stiffness, and the level of evidence is low. There is conflicting evidence as to the effect of therapeutic exercise on QoL.

Comparison 2.1: unsupervised HEP compared to supervised GE

Three studies compared the effectiveness of unsupervised HEP with supervised GE [26, 31, 32]. One study evaluated the effects of adding weekly GE to a HEP [27]. One threearmed study compared regular supervised GE, infrequent supervised individual exercise supplemented with a HEP and unsupervised HEP [20].

Function, QoL, disease activity, pain and stiffness

Physical function was assessed in four studies using different outcome measures (Fig. 3). Cagliyan et al. [32] found a significant difference favouring the GE, which was maintained at 3-month follow-up. They also found that QoL significantly favoured GE immediately after a 3-month intervention; only physical role difficulty subscore remained significantly superior at follow-up. Karapolat et al. [26] found GE to be equivalent to HEP in QoL, except in the sleep subscore in which GE was significantly superior.

Disease activity (BASDAI) was significantly lower following GE compared to HEP in the study by Cagliyan et al. [32]; however, Karapolat et al. [26] found no significant between-group differences. The effects of GE and HEP on resting pain, pain during activities and duration of morning stiffness were comparable [27, 31, 32].

Health-related fitness outcomes

No intergroup differences in spinal mobility were found across a variety of measures [20, 26, 31]. Cagliyan et al. [32] found that CE and finger-to-floor distance favoured HEP over GE, whereas intermalleolar distance was superior following GE; no differences were found at follow-up. Thoraco-lumbar flexion/extension was significantly superior following the addition of weekly GE to a HEP compared to HEP alone. Cervical rotation and CE were similar across groups [20, 27].

Hidding et al. [27] measured aerobic power with a maximal, incremental exercise test on a cycle ergometer. Maximum workload was significantly higher following GE compared to HEP. Analay et al. [31] compared VO_{2MAX} values obtained by the Åstrand test and found no significant between-group differences after exercise interventions or at follow-up.

Group exercise is more beneficial than HEP in improving QoL, and the level of evidence is moderate coming from two studies. There is no difference between supervised GE and HEP in physical function, pain and stiffness, and the level of evidence is moderate. There is no difference between GE and HEP for most spinal mobility, but the level of evidence is low. The findings of studies assessing disease activity and cardiorespiratory fitness are conflicting.

Comparison 2.2: global postural re-education

Function, QoL, disease activity, pain and stiffness

Three studies compared group GPR to GE [21, 22, 33], and one study compared individual GPR with GE [23]. This latter study favoured individual GPR over GE in physical function, physical aspects of QoL, pain scores and morning stiffness duration, but the level of evidence is very low coming from this single level III study. There was no significant difference between-group GPR and GE programmes in physical function and disease activity outcomes, and the level of evidence is moderate from one level II study [33]. There was no difference in the effectiveness of group GPR and GE programmes in QoL, but the level of evidence was very low coming from one level III study [21].

Health-related fitness outcomes

There is very low evidence coming from one level III study [23] that individual GPR is superior to conventional GE in improving spinal mobility and CE. No significant betweengroup differences in spinal mobility or PFTs were reported; the level of evidence for no difference is moderate and very low, respectively [22, 33].

Comparison 2.3: aerobic exercise

Karapolat et al. [38] investigated the effects of adding aerobic exercise to a stretching and mobility HEP. The addition of swimming to a HEP significantly increased walking distance on 6MWT test compared to HEP alone, but no significant between-group differences were observed in cardiorespiratory variables. Niedermann et al. [29] found that the addition of aerobic training to a flexibility programme increased cardiorespiratory fitness measured with a submaximal bicycle test, but did not result in a significant difference in cardiovascular risk factors (cholesterol and triglycerides). There is no significant between-group differences in disease activity, quality of life or spinal mobility, and the level of evidence is moderate coming from two level II studies.

Comparison 2.4: multimodal exercise programmes

Roşu et al. [39] compared two multimodal HEP. A group performing a multimodal HEP of breathing, postural and stretching exercises (based on the Pilates, Heckscher and McKenzie methods) had significantly improved disease activity, physical function, spinal mobility and vital capacity compared to an exercise programme that combined step-aerobics and stretching. The risk of bias within this study is high, and the quality of evidence is low.

Comparison 3: therapeutic exercise compared to other modalities

Inpatient rehabilitation

Figen et al. [19] compared a 3-week HEP with 3 weeks of inpatient rehabilitation. Will et al. [18] compared high-frequency inpatient exercise with supervised outpatient exercise, both supplemented by HEP. Comprehensive inpatient rehabilitation did not significantly change physical function, disease activity or spinal mobility compared to outpatient exercise; the level of evidence of no difference between HEP and inpatient rehabilitation is moderate coming from two studies.

Balneotherapy

Altan et al. [24] compared the effect of balneotherapy and HEP to HEP alone. Disease activity and QoL were significantly improved in the balneotherapy and HEP groups immediately after intervention, but equivalent at 24-week follow-up. No significant group differences were found in physical function, pain, morning stiffness duration or spinal mobility. The level of evidence is moderate coming from one level II study.

Incentive spirometry

The addition of incentive spirometry exercises to a HEP did not significantly improve physical function (BASFI or 6MWT), disease activity, PFTs or spinal mobility compared to HEP alone [25]; the level of evidence of no difference is moderate coming from one level II study.

Spa-exercise

of GE) with supervised GE. Data for the spa-exercise groups were pooled and compared to the supervised GE group. Pain and HAQ-S scores favoured the spa-exercise groups after the initial 3-week treatment at the spa centres. Pain remained significantly improved at 16 weeks, but this difference was no longer present 28 and 40 weeks into the intervention. The level of evidence from this single level II study is moderate.

Discussion

This review found evidence that therapeutic exercise has greater benefits than no intervention in improving physical function, disease activity, pain, stiffness, joint mobility and cardiovascular performance in adults with AS; evidence from trials examining QoL is conflicting. Exercise conducted under supervision has benefits over unsupervised HEP for QoL, but there is evidence of no difference, and conflicting evidence, across other outcomes. Spa-exercise and balneotherapy programmes have short-term benefits in QoL outcomes compared to GE; spa-exercise is also superior in pain relief, while balneotherapy further improves disease activity. Results from inpatient rehabilitation protocols were comparable to outpatient exercise protocols. These findings are in keeping with previous reviews [8, 40].

In comparisons of different exercise regimes, the addition of aerobic exercise to conventional stretching and mobility HEP results in superior functional fitness. Supplementing HEP with daily incentive spirometry does not yield additional benefits. Studies investigating different flexibility programmes have a high risk of bias; the GPR method delivered on an individual basis and a multimodal stretching and mobility programme appear superior to conventional exercise programmes.

The heterogeneity of exercise protocols and outcome measures employed preclude firm conclusions being drawn on the most effective exercise prescription. Vague descriptions of exercise protocols coupled with suboptimal dosage of exercise prescription, below that recommended to elicit physiological changes, add to the difficulty in assessing the impact of therapeutic exercise on SpA [41]. Furthermore, under-reporting of adherence to programmes was a feature of the included studies, making determining the efficacy of interventions problematic.

The outcome measures reported are principally selfreport in nature, with few studies assessing physiological measures. The investigation of the effects of exercise interventions on health-related fitness has centred on flexibility and cardiorespiratory domains; the effect of exercise on muscular strength and endurance, and body composition has not been investigated. Despite the increase in cardiovascular morbidity and mortality among SpA populations, the potential benefits of therapeutic exercise programmes on cardiovascular risk factor are yet to be adequately investigated in SpA [9].

Most benefits observed immediately post-intervention were not maintained at follow-up. The chronic nature of SpA requires ongoing, regular exercise; however, the optimal frequency necessary to maintain benefits is unknown. In the last two decades, the emergence of biologics has dramatically changed pharmacological approaches to the management of SpA. With improved management of inflammatory symptoms, there has been decreased compliance with exercise [42]. Regular involvement in exercise also declines with increased disease duration [43]; long-term compliance with exercise, particularly in people with lower disability levels, presents a clinical challenge.

Study limitations and future research

Non-randomised controlled trials were included in this review to increase the scope of the review, but simultaneously increased the risk of bias. It is a further constraint that data extraction was performed by one reviewer. In practice, therapeutic exercise is frequently prescribed as part of a multimodal treatment plan [30, 44]; this review excluded studies examining exercise therapy in combination with other modalities as the relative effect of exercise therapy would be unknown. Combining exercise prescription with other modalities may yield different outcomes.

Participants in the included studies were almost exclusively diagnosed with AS; extrapolating findings to other SpA subtypes should be undertaken cautiously. Future studies should account for the evolving classification of SpA (e.g. predominantly axial SpA or predominantly peripheral SpA) and explore the effects of exercise on other SpA subtypes. Furthermore, comprehensive reporting of exercise protocols and participant adherence rates in studies is essential to understanding the effectiveness of exercise therapy. Targeted exercise prescription should meet the dosage recommended to achieve physiological changes. Methodological quality among studies in this review was mixed. Random sequence generation, adequate allocation concealment and blinding of outcome assessment in future RCTs would go some way towards addressing methodological shortcomings.

Conclusions

Current evidence shows therapeutic exercise to be beneficial for adults with AS, although the effects on other SpA subtypes are unknown. Expanding traditional programmes of flexibility exercises to include aerobic components may improve clinical outcomes, although the most effective exercise protocol remains unclear. **Conflict of interest** The authors declare that they have no conflict of interest.

References

- Zochling J, Brandt J, Braun J (2005) The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford, England) 44(12):1483–1491
- Singh JA, Strand V (2009) Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 36(5):1012–1020. doi:10.3899/jrheum.081015
- Heikkila S, Viitanen JV, Kautiainen H, Kauppi M (2002) Functional long-term changes in patients with spondyloarthropathy. Clin Rheumatol 21(2):119–122
- 4. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783. doi:10.1136/ard.2009.108233
- Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31. doi:10.1136/ard.2010.133645
- 6. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904. doi:10.1136/ard.2011.151027
- Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394. doi:10.1136/ard.2008.094946
- Dagfinrud H, Kvien TK, Hagen KB (2008) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (1), Art No CD002822. doi:10.1002/14651858.CD002822.pub3
- Papagoras C, Voulgari PV, Drosos AA (2013) Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 31(4):612–620
- Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172
- Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://www.cochrane-handbook.org
- Durmus D, Alayli G, Uzun O, Tander B, Canturk F, Bek Y, Erkan L (2009) Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76(2):150–155. doi:10.1016/j.jbspin.2008.06.013
- 13. van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, The HG, van der

Linden S (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45(5):430–438

- Macedo LG, Elkins MR, Maher CG, Moseley AM, Herbert RD, Sherrington C (2010) There was evidence of convergent and construct validity of Physiotherapy Evidence Database quality scale for physiotherapy trials. J Clin Epidemiol 63(8):920–925. doi:10.1016/j.jclinepi.2009.10.005
- Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M (2003) Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther 83(8):713–721
- Oxford Centre for Evidence Based Medicine: Levels of Evidence Working Group (2011) The Oxford Levels of Evidence. http://www.cebm.net/index.aspx?o=5653. Accessed 1 Aug 2013
- Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406. doi:10.1016/j.jclinepi.2010.07.015
- Will RK, Suryana BPP, Lim A, Walsh E, Buchanan J (2003) Intensive exercise in patients with spondyloarthropathies—a randomized controlled study. Paper presented at the European League Against Rheumatism (EULAR) Annual Congress, Lisbon
- Figen A, Gecene M, Gunduz R, Borman P, Yorgancioglu R (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis. Turk J Rheumatol 26(2):135–144
- Ramos-Solchaga M, Ossorio Castellanos C, Garcia Soro JM (1998) Influencia de la terapia fisica mediante ejercicios en la evolucion a largo plazo de la espondilitis anquilosante. Rehabilitación (Madr) 32(5):316–323
- Rivera-Navarro J, Fernandez-De-Las-Penas C, Alonso-Blanco C, Miangolarra-Page JC (2005) Repercusiones en la calidad de vida en pacientes con espondilitis anquilosante mediante tratamiento fisioterápico. Fisioterapia 27(3):138–145
- Alonso-Blanco C, Rodriguez-López ESR, Fernández-de-las-Penas C (2009) Cambios espirometricos tras la aplicacion de un programa de cinesiterapia en la espondilitis anquilosante: estudio piloto. Fisioterapia 31(3):87–93
- Silva EM, Andrade SC, Vilar MJ (2012) Evaluation of the effects of Global Postural Reeducation in patients with ankylosing spondylitis. Rheumatol Int 32(7):2155–2163
- Altan L, Bingol U, Aslan M, Yurtkuran M (2006) The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol 35(4):283–289
- 25. So MW, Heo HM, Koo BS, Kim YG, Lee CK, Yoo B (2012) Efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy. J Rheumatol 39(9):1854–1858
- 26. Karapolat H, Akkoc Y, Sari I, Eyigor S, Akar S, Kirazli Y, Akkoc N (2008) Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 27(6):695–700. doi:10.1007/s10067-007-0765-0
- 27. Hidding A, van der Linden S, Boers M, Gielen X, de Witte L, Kester A, Dijkmans B, Moolenburgh D (1993) Is group physical therapy superior to individualized therapy in ankylosing spondylitis? Arthritis Care Res (Hoboken) 6(3):117–125
- Lim HJ, Moon YI, Lee MS (2005) Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 25(3):225–229
- 29. Niedermann K, Sidelnikov E, Muggli C, Dagfinrud H, Hermann M, Tamborrini G, Ciurea A, Bischoff-Ferrari H (2013)

Cardiovascular training improves fitness in patients with ankylosing spondylitis. Arthritis Care Res (Hoboken). doi:10.1002/ acr.22062

- Masiero S, Bonaldo L, Pigatto M, lo Nigro A, Ramonda R, Punzi L (2011) Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy. A randomized controlled trial. J Rheumatol 38(7):1335– 1342. doi:10.3899/jrheum.100987
- Analay Y, Ozcan E, Karan A, Diracoglu D, Aydin R (2003) The effectiveness of intensive group exercise on patients with ankylosing spondylitis [with consumer summary]. Clin Rehabil 17(6):631–636
- 32. Cagliyan A, Kotevoglu N, Onal T, Tekkus B, Kuran B (2007) Does group exercise program add anything more to patients with ankylosing spondylitis? J Back Musculoskelet Rehabil 20(2–3):79–85
- 33. Fernandez-de-las-Penas C, Alonso-Blanco C, Morales-Cabezas M, Miangolarra-Page JC (2005) Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am J Phys Med Rehabil 84(6):407–419
- Altan L, Korkmaz N, Dizdar M, Yurtkuran M (2012) Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int 32(7):2093–2099
- 35. Durmus D, Alayli G, Cil E, Canturk F (2009) Effects of a homebased exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int 29(6):673–677
- Ince G, Sarpel T, Durgun B, Erdogan S (2006) Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther 86(7):924–935
- Sweeney S, Taylor G, Calin A (2002) The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. J Rheumatol 29(4):763–766
- 38. Karapolat H, Eyigor S, Zoghi M, Akkoc Y, Kirazli Y, Keser G (2009) Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. Eur J Phys Rehabil Med 45(4):449–457
- 39. Rosu MO, Topa I, Chirieac R, Ancuta C (2013) Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. Rheumatol Int. doi:10.1007/s00296-013-2869-y
- Ribeiro F, Leite M, Silva F, Sousa O (2007) Physical exercise in the treatment of Ankylosing Spondylitis: a systematic review. Acta Reumatol Port 32(2):129–137
- 41. Dagfinrud H, Halvorsen S, Vollestad NK, Niedermann K, Kvien TK, Hagen KB (2011) Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness? Arthritis Care Res (Hoboken) 63(4):597–603. doi:10.1002/acr.20415
- Falkenbach A (2003) Disability motivates patients with ankylosing spondylitis for more frequent physical exercise. Arch Phys Med Rehabil 84(3):382–383
- Passalent LA, Soever LJ, O'Shea FD, Inman RD (2010) Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 37(4):835–841. doi:10.3899/jrh eum.090655
- 44. Rodriguez-Lozano C, Juanola X, Cruz-Martinez J, Pena-Arrebola A, Mulero J, Gratacos J, Collantes E (2013) Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study. Clin Exp Rheumatol 31(5):739–748